Skip to main content
OpenTrials
Completed

NCT Number: NCT07182903

Fatigue in MS: From Invisible to Measurable

Fatigue is one of the most common and burdensome symptoms of MS, but its precise cause remains unknown, and an effective treatment is lacking. Previous research has shown that the progression of MS is associated with a higher presence of a specific type of T-cell, the cytotoxic CD4+ T-cells, which play a role in the immune system.

The aim of this study is to investigate whether these cells can also be linked to fatigue in people with MS.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Fatigue Immune System Diseases Nervous System Diseases Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Observational

Primary location

UMCG

Groningen, Netherlands

About this study

Forty individuals with MS will be asked to complete questionnaires about fatigue and perform motor tasks. Additionally, blood samples will be taken to measure the levels of cytotoxic CD4+ T-cells. These values will then be correlated with fatigue scores and performance on the motor tasks.

Scores from the fatigue questionnaires and decline in amplitude and frequency from the performance fatiguability test will be correlated to the level of CD4 CTLs from the blood samples. Secondary study parameters include muscle activation patterns measured by EMG, distance walked on 6MWT and voluntary muscle activation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of relapsing remittion, primary progressive or secondary progressive MS
  • Age: 18-60 years
  • Ability to perform the foot-tapping task
  • Ability to walk at least 20 meters (with or without walking aid)

Exclusion criteria

  • Dimethyl fumarate, fingolimod or alemtuzumab treatment, since these medications have a strong influence on the immune system As a result of these treatments, there are few to no immune cells circulating in the blood, meaning we cannot find our population of interest in the blood.
  • Change in medication 6 weeks before the start of the study (including medication not related to MS) - MS relapse within 6 weeks of the start of the study
  • Had an infection in the last month - Received a vaccination in the last 14 days - Pregnant or pregnancy in the last 6 months
  • Having a psychiatric disorder
  • Having a neurological disorder other than MS
  • Having cognitive or communicative problems that makes it hard to follow instructions

Treatment and study plan

Primary outcomes

  1. Correlation between percentage of cytotoxic CD4+ T cells and FSS score

    Time frame: Day 1

    Bivariate correlations will be calculated between the percentage of cytotoxic CD4+ T cells and fatigue, measured with Fatigue Severity Scale (FSS).

  2. Correlation between percentage of cytotoxic CD4+ T cells and MFIS score

    Time frame: Day 1

    Bivariate correlations will be calculated between the percentage of cytotoxic CD4+ T cells and fatigue, measured with Modified Fatigue Impact Scale (MFIS).

  3. Correlation between percentage of cytotoxic CD4+ T cells and foot-tapping frequency decrease

    Time frame: Day 1

    Bivariate correlations will be calculated between the percentage of cytotoxic CD4+ T cells and fatigability, measured as the decrease in frequency from the first 10 seconds of the task to the last 10 seconds of the task.

  4. Correlation between percentage of cytotoxic CD4+ T cells and foot-tapping amplitude decrease

    Time frame: Day 1

    Bivariate correlations will be calculated between the percentage of cytotoxic CD4+ T cells and fatigability, measured as the decrease in amplitude from the first 10 seconds of the task to the last 10 seconds of the task.

Secondary outcomes

  1. Changes in muscle activation during 6MWT

    Time frame: Day 1

    Comparison of the root-mean-square (RMS) of the EMG signal at the beginning of the task and the end of the task.

  2. Changes in muscle activation during foot tapping task

    Time frame: Day 1

    Comparison of the root-mean-square (RMS) of the EMG signal at the beginning (first 10 seconds) of the task and the end (last 10 seconds) of the task.

  3. Correlation changes in walking distance between the first and last minute of the 6MWT and CD4+ CTLs

    Time frame: Day 1

    Changes in distance between the first minute and the last minute of the 6MWT are measured to assess walking fatigability and will be correlated with the percentage of CD4+ CTLs in the blood.

  4. Correlation percentage voluntary muscle activation and CD4+ CTLs

    Time frame: Day 1

    The correlation is calculated between the percentage of CD4+ CTLs in the blood and the percentage of voluntary activation (1 - superimposed twitch/initial-doublet) x 100%).

Sponsors and collaborators

Lead sponsor

University Medical Center Groningen

Other

Collaborators

  • UHasselt

Registry information

Acronym: FIMS

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Sep 19, 2025
Registry last updated
Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.